A novel human leukemic cell line, TMD2, which proliferates dependently on interleukin-3 (IL-3). was established from the peripheral blood (PB) of a patient with chronic lymphocytic leukemia (CLL) in the acute phase. After 8 years of the chronic phase of CLL, lymphoblastoid cells appeared and became dominant in the PB. After repeated subcultures of the patient's PB cells in the acute phase, lymphoblastoid cells have proliferated actively in the presence of recombinant human IL-3, and the TMDZ cell line has been established. The lymphoblastoid cells in acute phase and TMDZ cells proliferated dependently on IL-3, whereas growth of the small lymphocytes in chronic phase was not supported by IL-3. Other ILs (lL-l,2, and 4 through 6) or CSF did not support the growth or survival of TMDZ cells. The existence of high-CELL LINE whose growth depends on a certain A cytokine is a useful tool for analyzing the action of the cytokine on cellular growth, differentiation, and maturation. Especially the receptors or signal transduction of the cytokine will be determined well if an appropriate cytokinedependent cell line is provided. With the various murine interleukin-3 (IL3)-dependent cell lines that have been established, the signal transduction of IL-3 was recently elucidated.'.' In contrast, little is known about the postreceptor signal of IL-3 in human cells.' To clarify the precise mechanism by which human IL-3 acts on human cells, a study using human IL-3-dependent cell line is desirable. A few human cell lines that respond not only to IL-3 but also to other cytokines such as GM-CSF have been establ i~h e d .~.~ The action of IL-3 can be examined with these cell lines, but in them the interaction between IL-3 and GM-CSF should always be considered because GM-CSF may modulate signal transduction of IL-3.
A cytokine is a useful tool for analyzing the action of the cytokine on cellular growth, differentiation, and maturation. Especially the receptors or signal transduction of the cytokine will be determined well if an appropriate cytokinedependent cell line is provided. With the various murine interleukin-3 (IL3)-dependent cell lines that have been established, the signal transduction of IL-3 was recently elucidated.'.' In contrast, little is known about the postreceptor signal of IL-3 in human cells. ' To clarify the precise mechanism by which human IL-3 acts on human cells, a study using human IL-3-dependent cell line is desirable. A few human cell lines that respond not only to IL-3 but also to other cytokines such as GM-CSF have been establ i~h e d .~.~ The action of IL-3 can be examined with these cell lines, but in them the interaction between IL-3 and GM-CSF should always be considered because GM-CSF may modulate signal transduction of IL-3.
We report the establishment of the novel human IL-3-dependent lymphoid leukemic cell line designated TMD2. The cell line was established from a patient with chronic lymphocytic leukemia (CLL) in the acute phase. To our knowledge, a cell line established from CLL in the acute phase has not yet been reported, although several cell lines from chronic myelocytic leukemia (CML) in blastic transformation, such as K562, have been reported. ' We consider the TMD2 cell line a useful tool for studying the action of IL-3 in cellular growth. Furthermore, the TMD2 cell line will be a valuable model of CLL in the acute phase.
MATERIALS AND METHODS
A 67-year-old man was hospitalized at Tokyo Metropolitan Komagome Hospital in June 1990 because of marked splenomegaly. He had had CLL since 1982. On his admission, his W C count was 303,600lpL with 76% large lymphoblastoid cells, 21% small lymphocytes, and 3% neutrophils. The lymphoblastoid cells were larger than CLL cells and had a relatively abundant cytoplasm, an irregular nuclear outline, fine chromatin condensation, and several nucleoli. He was diagnosed as having CLL in the acute phase or lymphoblastic transformation and received cyclophosphamide, vincristine, adriamycin, and prednisolone. After the chemotherapy, most of the lymphoblastoid cells disappeared from the peripheral blood (PB) and the disease progressed to the chronic
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affinity receptors for IL-3 was shown on TMDZ cells (binding sites 88 per cell, Kd = 76.9 pmol/L). DNA extracted from the small lymphocytes in the chronic phase, the lymphoblastoid cells in the acute phase, and TMDZ cells showed the same rearrangement pattern of the immunoglobulin heavy-chain gene. Therefore, these cells were considered to have originated from the same clone. These results imply that a genetic event that caused the responsiveness to IL-3 in the cell of the chronic phase caused the acute transformation of CLL in this patient. We consider that TMDZ cell line is valuable as a model of cells of CLL in the acute phase and as a tool for studying the signal transduction system of IL-3. @ 1991 by The American Society of Hematology.
phase. Soon, however, the lymphoblastoid cells again became dominant and repeated chemotherapy was required (Y. Maruyama, manuscript in preparation).
Mononuclear cells were separated by FicollHypaque density gradient (1.077 g/mL) from the patient's PB in the acute phase, with his informed consent. The cells were plated in a 24-well plate (Falcon, Oxford, CA) at 1 X lo6 cells/mL in a-minimal essential medium (a-MEM; GIBCO, Grand Island, NY) with 20% fetal calf serum (FCS, GIBCO) and 5 ng/mL recombinant human IL-3 (rhIL-3, Genzyme, Boston, MA). rhIL-3 was produced using a cDNA obtained from activated T cells' and expressed in yeast. The purity of rhIL-3 is 95%, as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) in gels developed with silver staining before addition of carrier protein. Approximate specific activity is 5.0 x lo7 proliferation units per milligram, as determined by the proliferation assay measuring human bone marrow (BM) precursor cell incorporation of 'H-TdR in a 96-hour microassay (Genzyme). The cultures were incubated at 37°C in a humidified atmosphere of 5% CO, in air. Every 4 days, half the medium was exchanged with fresh medium. The cells have proliferated exponentially, and a new cell line established after repeated subcultures has been designated ThlD2.
Cellular morphology, cytochemistry, immunophenotype, and karyotype. The cells were placed on a glass slide using Cytospin 2 (Shandon, London) and stained with Wright's stain, peroxidase staining (POX), periodic acid-Schiff staining (PAS), and a-naphtyl butyrate and naphthol AS-D chloroacetate esterase dual stain. Cell surface antigens of TMD2 cells, the small lymphocytes obtained from the patient in the chronic phase, and the large lymphoblistoid cells from the patient in the acute phase were analyzed with FACStar (Becton-Dickinson, Mountain View, CA) with commerCell culture.
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Submitted December 4,1990; DNA was extracted from TMD2 cells and mononuclear cells separated from the PB (PBMNC) of the patient in chronic and acute phases. Human placenta DNA was used as a control. The samples of DNA were digested with HindIII, EcoRI, or EamHI, electrophoresed, transferred by Southern blotting technique, hybridized to 32P-labeled probe, and visualized on autoradiograms." The probes used were the IgH gene joining region JH probe [3.4-kilobase (kb) EcoRI-Hind111 fragment], CTp probe, bcl-2 probe (Oncor) and c-myc third exon probe (all from Oncor, Gaithersburg, MD).
To determine the growth factor essential for optimal proliferation of TMD2 cells, the proliferation of TMD2 cells stimulated with various cytokines was examined by colorimetric assay as described by Mosmann" and by the clonogenic assay as described by Nara and McCulloch." The cytokines studied were rhIL-la and rhIL-P (gifts from Dr Y. Hirai, Ohtsuka Pharmaceutical, Tokushima, Japan), rhIL-2, rhIL-3, rhIL-4, rhIL-6 (Genzyme), rhIL-5 (Amersham, Buckinghamshire, England), rhGM-CSF (Hoechst Japan, Tokyo), rhG-CSF, rh-erythropoietin (rhEPO, Chugai Pharmaceutical, Tokyo), and rhM-CSF (Ohtsuka Pharmaceutical).
In the colorimetric assay (MTT assay), lo4 TMD2 cells were incubated in a 96-microwell microplate (Sumitomo Bakelite, Osaka, Japan) in 0.1 mL RPMI 1640 medium (GIBCO) with 10% FCS (GIBCO) with some cytokine at 37°C in a humidified atmosphere of 5% CO, in air. After 5-day incubation, MTT (3-[4, 5-dimethylthiazol-2-y1]-2, 5-diphenyl tetrazolium bromide, Sigma Chemical, St. Louis, MO) was added and incubated for 4 more hours. Isopropanol containing 0.04 N HC1 was then added, and optical density (OD) was measured with an enzyme-linked immunosorbent assay (ELISA) reader using test and reference wavelengths of 570 and 620 nm, respectively.
When lo4 TMD2 cells were plated in a 96-microwell plate in 0.1 mL a-MEM with 20% FCS, 0.8% methylcellulose (Dow Chemicals, Midland, MI) with 1 to 10 ng/mL rhIL-3, colonies of more than 20 cells formed after 7-day incubation at 37T, 5% CO, in air. The effect of other cytokines on colony formation of TMD2 was tested. Furthermore, the effect of anti-IL-3 antibody on colony formation stimulated by 5 ng/mL rhIL-3 was examined. Mouse anti-human IL-3 MoAb was purchased from Genzyme. This anti-IL-3 antibody has been shown by ELISA and dot-blot analysis to bind rhIL-3, and 0.5 mg of this antibody neutralizes approximately 2,500 U rhIL-3. No detectable cross-reactivity of this antibody with rhIL-2, IL-4, or GM-CSF has been observed. Because this antibody class was IgG,, mouse IgG, (ICN Biomedicals, Lisle, IL) was used as a control.
To detect the specific IL-3 receptors on TMD2 cells, binding studies using 'zsI-IL-3 were performed by a previously described method"; 7.0 x lo6 cells in 200 pL binding buffer (RPMI 1640 medium supplemented with 0.1% bovine serum albumin (Sigma) and 10 mmol/L 4-[2-hydroxyethyI]-l-piperazineethanesulfonic acid (Sigma), pH = 7.4) containing IzI-IL-3 at various concentrations with or without a 100-fold excess of unlabeled IL-3 were incubated for 2 hours at 18°C in Micro Labtubes (Ieda Trading, Tokyo) with gentle continuous mixing. "'I-IL-3 was purchased from Amersham Japan. 'ZSI-Labeled rhIL-3 was prepared by the method based on that of Bolton and Hunter14 and was purified by gel-filtration high-performance liquid chromatography. The specific activity was 18.5 TBqimmol. After the cells were incubated with IzI-IL-3, bound and free '251-IL-3 were separated by removing duplicate 80-pL aliquots from the incubation mixture, layering those on 100 pL di-n -butyl phthalate (Wako Pure Chemical Industries, Osaka, Japan) in tapered 400-)1L Micro Labtubes, and centrifuging for 2 minutes at 10, OOOg. The oil Southem blot analysis.
Effects of cytokines on the proliferation of TMD2 cells.
Binding of '"I-IL-3 to cells. allowed cells to sediment but was more dense than binding buffer. After aspiration of the supernatants, the lower layer containing the cell pellets was cut off by scissors, and the radioactivity was counted in a y-counter. Radioactivity bound to cells in the presence of 100-fold excess of unlabeled IL-3 was considered nonspecific binding and was subtracted from the total binding.
To rule out contamination of TMD2 cells by Epstein-Barr virus (EBV), EBV nuclear antigen (EBNA) was tested by the method of Reedman and Klein." Viral study. Proliferation in culture of TMDZ cells was studied by colorimetric assay and clonogenic assay to determine the growth factor(s) ncccssary for optimal proliferation of TMD2 cells. Growth requirement of TMD2 cel1.7.
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TMD2 cells, PBMNC in chronic phase and PRMNC in For personal use only. on October 23, 2017 . by guest www.bloodjournal.org From but 0.02 to 5.0 ng/mL IL-3 did not stimulate proliferation of PBMNC in the chronic phase. The proliferative activity of TMD2 cells and PBMNC in the acute phase appeared to reach plateau by IL-3 at a concentration greater than 2.5 ng/mL. When TMD2 cells were plated in methylcellulose media with IL-3 added, colonies of more than 20 cells formed. Colonies were picked using a fine micropipette, placed on a glass slide, stained by Wright's stain, and examined morphologically. The colonies were thus confirmed to be composed of cells with the morphologic appearance of TMD2 cells. rhIL-3 stimulated colony formation in a dose-responsive manner, as shown by MTT assay; 2 ng/mL IL-3 showed almost maximal effect on colony formation of TMD2 cells (data not shown). Figure 4 shows the time-course of TMD2 cell proliferation. Cultured with rhIL-3, TMD2 cells proliferated exponentially. Without IL-3, although viable cell number increased slightly until day 7, most cells ceased to proliferate after the day 8.
Next, we attempted to clarify whether other cytokines also were effective on proliferation of TMD2 cells. First, proliferation of TMD2 cells was assessed by MTT assay with some cytokine added. The cytokines tested were rhIL-la (100 U/mL), rhIL-lP (100 U/mL), rhIL-2 (1,000 U/mL), rhIL-4 (100 U/mL), rhIL-5 (5 ng/mL), rhIL-6 (100 ng/mL), rhGM-CSF (10 ng/mL), rhG-CSF (10 ng/mL), rhM-CSF (1,000 U/mL), and rh-EPO (10 U/mL). The concentration of each cytokine was chosen because results of our previous published and unpublished studies showed that each cytokine at each concentration displayed some effects on leukemia These cytokines did not stimulate or suppress proliferation of TMD2 cells in M'IT assay. Neither were PBMNC in the chronic and acute phases affected by these cytokines. Second, we examined the effect of 1 to 100 ng/mL rhGM-CSF or G-CSF on the growth of TMD2 cells in the clonogenic assay. Neither GM-CSF nor G-CSF stimulated colony formation of TMD2 cells at concentrations of 1 to 100 ng/mL.
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The above data suggest that TMD2 cells require IL-3 exclusively for their growth. To confirm this hypothesis, we tested whether anti-IL-3 antibody released the stimulatory effect of IL-3 on TMD2 cells. TMD2 cells were plated in methylcellulose media in the presence of 5 ng/mL rhIL-3; 0.05 to 100 pg/mL anti-human IL-3 MoAbs were added to the culture of TMD2 cells. After 7-day incubation, colonies of more than 20 cells were counted. Figure 5 shows the effect of anti-IL-3 antibody on colony formation of TMD2 cells. Anti-IL-3 antibody reduced colony formation stimulated by 5 ng/mL IL-3, and 50 kg/mL anti-IL-3 antibody completely abolished the stimulatory effect of IL-3 on TMD2 cells. Mouse IgG,, used as a control, did not significantly affect colony formation of TMD2 cells.
To confirm further the role of IL-3 on proliferation of TMD2 cells, we investigated the expression of IL-3 receptors on TMD2 cells. Figure 6A linearly with an increase in radioligand. A plot of specific binding as a function of radioligand concentration indicates that binding was dose responsive and saturable. Scatchard plot analysis of the binding data yielded an apparent kd of 76.9 pmol/L with 88 binding sites per cell (Fig 6B) . Fewer IL-3 receptors were expressed on TMD2 than were expressed on some strains of human myeloid leukemia cell line KG-1, which had a single class of high-affinity receptors (240 to 310 receptors per cell) with a kd of approximately 100 pmol/L."
DISCUSSION
We have established a novel IL-3-dependent cell line, TMD2, from a patient with CLL in the acute phase. To our knowledge, a cell line established from CLL in the acute phase has not yet been reported. Therefore, the TMD2 cell line may be useful as model of CLL cells in acute transformation just as the K562 cell line has proved to play important roles in studies of CML in blast tran~formation.~
The morphology and phenotypes of TMD2 cells were similar to those of lymphoblastoid cells of the patient in the acute phase (Fig 1) . The responsiveness to IL-3 of TMD2 cells was also similar to that of the lymphoblastoid cells in the acute phase (Fig 3) . These findings support the hypothesis that the TMD2 cell line is a clonal expansion from the original leukemic cells of the patient. In contrast, TMD2 cells were different from the CLL cells of the patient in the chronic phase in terms of the morphology, phenotypes, and responsiveness to IL-3, but DNA showed the same rearrangement pattern of the immunoglobulin heavy-chain gene among TMD2 cells, lymphoblastoid cells in the acute phase, and lymphocytes in the chronic phase (Fig 2) . Therefore, TMD2 cells, lymphoblastoid cells in the acute phase, and lymphocytes in the chronic phase were considered to have originated from the same clone. During the long-term clinical course, CLL cells are believed to have made a transformation, resulting in lymphoblastoid cells. Although CLL cells in the chronic phase did not respond to IL-3, lymphoblastoid cells in the acute phase proliferated actively by stimulation of IL-3. Some CLL cell(s) in the chronic phase may have acquired responsiveness to IL-3, responded to IL-3, transformed, and obtained high proliferative activity. Alternatively, in the process of transformation, CLL cells may have acquired responsiveness to IL-3.
IL-3 stimulated proliferation of TMD2 cells in a doseresponsive manner. The maximal proliferation of TMD2 was induced by 2.5 ng/mL rhIL-3 assessed by MTT assay, and half-maximal proliferation was obtained by approximately 0.3 ng/mL rhIL-3 (Fig 3) . This dose-response curve was similar to that observed in another IL-3-dependent cell line, TF-1 established from erythroleukemia; 1 ng/mL and 0.03 to 0.1 ng/mL rhIL-3 induced maximal and halfmaximal proliferation of TF-1 cells, respectively.' Although the responsiveness to IL-3 of TMD2 cells was comparable to that of TF-1, the growth requirement of these cell lines was different. TMD2 responded only to IL-3, whereas TF-1 responded not only to IL-3 but also to GM-CSF and EPO.
To demonstrate further the specificity of the IL-3 effect on TMD2 cells, we investigated whether TMD2 expressed receptors for IL-3 and whether an anti-IL-3 antibody blocked the effect of IL-3 on proliferation of TMD2 cells. TMD2 cells possessed high-affinity receptors for IL-3 ( Fig  6) , although their number was quite small as compared with those of IL-3 receptors expressed on some strains of the KG-1 cell line." Furthermore, anti-IL-3 MoAb completely released the stimulatory effect of IL-3 on TMD2 cells (Fig  5) . On the basis of these findings, the TMD2 cell line is a quite novel IL-3-dependent lymphoid cell line that expresses surface immunoglobulin Mk and contains the rearrangement of immunoglobulin heavy chain. The TMD2 cell line, therefore, will be a valuable tool for studying signal transduction system of hIL-3. So far, some murine IL-3-dependent cell lines have played an important role in studying signal transduction of IL-3,= but the signals of For personal use only. on October 23, 2017 . by guest www.bloodjournal.org From murine IL-3 are not necessarily the same as those of hIL-3. Therefore, an hIL-34ependent cell line is required to explore the signal transduction system of IL-3 in human cells. Human cell lines that respond to both IL-3 and GM-CSF have been reported?-6 With these cell lines, signal transduction of human IL-3 has been studied? Because IL-3 and GM-CSF have been believed to induce a nearly identical tyrosine phosphorylation, however, the possibility that IL-3 stimulates not only signal transduction system of IL-3 but also that of GM-CSF cannot be excluded. Therefore, the TMD2 cell line, which responds only to IL-3 but not to GM-CSF, can be expected to serve as a suitable model for studying the signal transduction system of IL-3 in human cells.
